Management
Bo Rode Hansen
President & Chief Executive Officer
Education: MSc, PhD, MBA
Background: President and CEO of Genevant Sciences Inc.; Global Head of Roche RNA Therapeutics & General Manager of Roche Innovation Center Copenhagen; Executive, VP & Head of Drug Discovery & Alliance at Santaris Pharma (acquired by Roche).
Other ongoing assignments: Advisor for Novo Seeds
Scandion Oncology shares and warrants
42,442 shares and 1,071,688 warrants
Maj Hedtjärn
Chief Operating Officer and Head of R&D Operations
Education: MSc, PhD
Background: Dr. Maj Hedtjärn has held numerous leadership positions within R&D in biotech and pharma (Roche, Santaris Pharma and Lundbeck), most recently as VP, Head of Drug Discovery, RNA Therapeutics Research at Roche. Maj has extensive experience in drug discovery & development, program leadership, building portfolios across different disease areas, big pharma partnerships, alliance management, executive leadership and developing and implementing scientific and business strategies.
Other ongoing assignments: Scientific Advisor for Lipigon Pharmaceuticals AB
Scandion Oncology shares and warrants
24,000 shares (owned via Venilia Holding ApS)
Johnny Stilou
Chief Financial Officer
Education: MSc in Business Economics and Auditing, Executive Management Program, INSEAD.
Background: Johnny Stilou has held numerous Executive positions as Chief Financial Officer within biotech and pharma. Most recently as CFO at Amgen Research Copenhagen and Nuevolution AB (acquired by Amgen). Previously he was CFO at Veloxis Pharmaceuticals (acquired by Asahi Kasei).
Other ongoing assignments: None
Scandion Oncology shares and warrants
10,000 shares
Jan Stenvang
Chief Technology Officer
Education: MSc, PhD
Background: Co-founder of Scandion Oncology. Associate Professor at the University of Copenhagen since 2013. Researcher at the Danish Cancer Society concerning gene regulation and anti-estrogen-resistant breast cancer. Jan has authored 89 publications, most of which relate to translational cancer research, biomarkers and drug resistance.
Other ongoing assignments: Associate Professor, University of Copenhagen.
Co-founder of Scandion Oncology A/S.
Scandion Oncology shares and warrants
1,371,519 shares
Peter Michael Vestlev
Chief Medical Officer
Education: MD, CBA, MPP
Background: Chief Physician, Oncologist, Region Zealand and Capital Region Previously, Head of Radiotherapy unit, Herlev Hospital, Head of Cooperating Cancer Departments, Head of research unit Roskilde Hospital, consultant for the Danish Medicines Agency, Chief Oncologist Capital Region.
Other ongoing assignments: External lecturer at Roskilde University. Consultant Region Zealand department of oncology.
Scandion Oncology shares and warrants
195,700 shares and 53,584 warrants
Nicklas Lindland Roest
Chief Regulatory Officer
Education: MSc, Pharm
Background: Project manager and regulatory/CMC specialist within the pharmaceutical and biotech industry.
Other ongoing assignments: None
Scandion Oncology shares and warrants
34,188 shares and 53,585 warrants (Partly owned via Lindland Roest Holding ApS)
Annie Rasmussen
Chief Clinical Officer
Education: RN, Master of Public Health
Background: Extensive Oncology Clinical Research & Operational experience from Oncology Clinics & Research Units, Smithkline Beecham and Biotech Companies since 1982.
Former President of the Danish Oncology Nursing Society, Previous Co-founder & CCO of Topotarget A/S & EVP Clinical Operations Oncology Venture A/S. Founder of Health- CreationDK and CancerGuidesDK.
Other ongoing assignments: Board Member of North Star Group A/S.
Scandion Oncology shares and warrants
20,000 shares and 53,585 warrants
Mads Aaboe Jensen
VP, Business Development and Innovation
Education: MSc, PhD
Background: Business development, search & evaluation and R&D in biotech and pharma.
Other ongoing assignments: None
Scandion Oncology shares and warrants
11,000 shares
Mads Kronborg
Head of External Communication
Education: BA
Background: Head of Corporate Media Relations at H. Lundbeck A/S, Head of Corporate Communication at H. Lundbeck A/S, Head of Investor Relations and Communication at Zealand Pharma A/S.
Other ongoing assignments: Independent consultancy assignments.
Scandion Oncology shares and warrants: None
